Sign In
Buy NKTR
$59.23
+0.670 (+1.14%)
At Close: Jun 03, 2026
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers – NKTR
03:27pm, Tuesday, 10'th Mar 2026
NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR) and certa
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm
01:00pm, Tuesday, 10'th Mar 2026
LOS ANGELES, March 10, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Nektar Therapeutics (“Nektar�
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their Options If you purchased or acquired
Nektar Therapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – NKTR
08:30am, Tuesday, 10'th Mar 2026
LOS ANGELES--(BUSINESS WIRE)--Nektar Therapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – NKTR.
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm
08:08pm, Monday, 09'th Mar 2026
LOS ANGELES--(BUSINESS WIRE)---- $NKTR--NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm.
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit
04:21pm, Monday, 09'th Mar 2026
NEW YORK, March 9, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Nektar Therapeutics (NASDAQ: N
SAN DIEGO, March 9, 2026 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Nektar Therapeutics (NASDAQ: NKT
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Nektar Therapeutics (NKTR)
12:38pm, Monday, 09'th Mar 2026
NEW YORK, March 09, 2026 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Northern District of
Rosen Law Firm Urges Nektar Therapeutics (NASDAQ: NKTR) Stockholders to Contact the Firm for Information About Their Rights
12:29pm, Monday, 09'th Mar 2026
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between Febru
ATLANTA, March 09, 2026 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Nektar Therapeutics (“Nektar”) (NASDAQ: NKTR). The lawsuit alleges that Defendants issued fals
Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of Nektar Therapeutics, (NKTR)
07:10am, Monday, 09'th Mar 2026
Philadelphia, Pennsylvania--(Newsfile Corp. - March 9, 2026) - WHAT IS HAPPENING? Grabar Law Office is investigating claims on behalf of shareholders of Nektar Therapeutics (NASDAQ: NKTR).
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their Options If you purchased or acquired
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06:00pm, Friday, 06'th Mar 2026
SAN FRANCISCO, March 6, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that, on February 20, 2026, the Organization and Compensation Committee of Nektar's Board of Directors g
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their Options
Investor Notice: Robbins LLP Informs Investors of the Nektar Therapeutics Class Action Lawsuit
04:48pm, Friday, 06'th Mar 2026
SAN DIEGO--(BUSINESS WIRE)---- $NKTR #ET--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Nektar Therapeutics (NASDAQ: NKT
